Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow

DETAILED DESCRIPTION OF THE INVENTION The compounds of the present invention, which are selective to the .
beta.
2 containing nicotinic acetylcholine receptors, include compounds of the Formula I: ##STR1## where X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, often greater than 0.
1, and generally greater than 0.
2, and even greater than 0.
3; less than 0 and generally less than -0.
1; or 0; as determined in accordance with Hansch et al.
, Chem.
Rev.
91:165 (1991); n is an integer which is 1, 2, 3, 4, 5, 6, 7, or 8, preferably is 1, 2, or 3, and most preferably is 2 or 3; E' represents hydrogen or lower alkyl (e.
g.
, straight chain or branched alkyl including C.
sub.
1 -C.
sub.
8, preferably C.
sub.
1 -C.
sub.
5, such as methyl, ethyl, or isopropyl) or halo substituted lower alkyl (e.
g.
, straight chain or branched alkyl including preferably C.
sub.
1 -C.
sub.
8, preferably C.
sub.
1 -C.
sub.
5, such as trifluoromethyl or trichloromethyl), but preferably is H; E" represents lower alkyl (e.
g.
, straight chain or branched alkyl including preferably C.
sub.
1 -C.
sub.
8, preferably C.
sub.
1 -C.
sub.
5, such as methyl, ethyl, or isopropyl) or halo substituted lower alkyl (e.
g.
, straight chain or branched alkyl including C.
sub.
1 -C.
sub.
8, preferably C.
sub.
1 -C.
sub.
5, such as trifluoromethyl or trichloromethyl); Z' and Z" individually represent hydrogen or lower alkyl (e.
g.
, straight chain or branched alkyl including C.
sub.
1 -C.
sub.
8, preferably C.
sub.
1 -C.
sub.
5, such as methyl, ethyl, or isopropyl), and preferably at least one of Z' and Z" is hydrogen, and most preferably Z' is hydrogen and Z" is methyl; alternatively Z' is hydrogen and Z" represents a ring structure (cycloalkyl or aromatic), such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, quinuclidinyl, pyridinyl, quinolinyl, pyrimidinyl, phenyl, or benzyl (where any of the foregoing can be suitably substituted with at least one substituent group, such as alkyl, halo, or amino substituents); alternatively Z', Z", and the associated nitrogen atom can form a ring structure such as aziridinyl, azetidinyl, pyrollidinyl, piperidinyl, piperazinyl, or morpholinyl; A, A' and A" individually represent hydrogen, halo (e